Genomic and clinical predictors of lacosamide response in refractory epilepsies.

Détails

Ressource 1Télécharger: 31819912_BIB_E8A0DD5EBEC6.pdf (382.59 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_E8A0DD5EBEC6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Genomic and clinical predictors of lacosamide response in refractory epilepsies.
Périodique
Epilepsia open
Auteur(s)
Heavin S.B., McCormack M., Wolking S., Slattery L., Walley N., Avbersek A., Novy J., Sinha S.R., Radtke R., Doherty C., Auce P., Craig J., Johnson M.R., Koeleman BPC, Krause R., Kunz W.S., Marson A.G., O'Brien T.J., Sander J.W., Sills G.J., Stefansson H., Striano P., Zara F., Depondt C., Sisodiya S., Goldstein D., Lerche H., Cavalleri G.L., Delanty N.
Collaborateur(s)
EPIGEN Consortium, EpiPGX Consortium
ISSN
2470-9239 (Print)
ISSN-L
2470-9239
Statut éditorial
Publié
Date de publication
12/2019
Peer-reviewed
Oui
Volume
4
Numéro
4
Pages
563-571
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real-world clinical setting.
We tested the association of clinical predictors with treatment response using regression modeling in a cohort of people with refractory epilepsy. Genetic assessment for lacosamide response was conducted via genome-wide association studies and exome studies, comprising 281 candidate genes.
Most patients (479/483) were treated with LCM in addition to other AEDs. Our results corroborate previous findings that patients with refractory genetic generalized epilepsy (GGE) may respond to treatment with LCM. No clear clinical predictors were identified. We then compared 73 lacosamide responders, defined as those experiencing greater than 75% seizure reduction or seizure freedom, to 495 nonresponders (<25% seizure reduction). No variants reached the genome-wide significance threshold in our case-control analysis.
No genetic predictor of lacosamide response was identified. Patients with refractory GGE might benefit from treatment with lacosamide.
Mots-clé
GWAS, lacosamide, pharmacogenomics, pharmacoresistance, refractory
Pubmed
Open Access
Oui
Création de la notice
29/09/2020 13:42
Dernière modification de la notice
15/01/2021 8:12
Données d'usage